Understanding how epigenetic changes can increase lung cancer risk
Defining signatures of epigenetic sensitization to lung cancer in a mouse model
This study is looking at how changes in the way genes are turned on or off in lung tissue might help us spot the risk of lung cancer early on, using mice to find clues that could lead to better ways to diagnose and treat lung cancer for patients like you.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10862318 on NIH RePORTER |
What this research studies
This research investigates how specific epigenetic changes in lung tissue can influence the development of lung cancer. Using a mouse model, the study aims to identify early epigenetic signatures that may predict cancer risk before tumors actually form. By examining the effects of genetic mutations and epigenetic alterations, the research seeks to improve risk stratification and treatment targeting for lung cancer patients. The findings could lead to better diagnostic tools and therapeutic strategies based on individual epigenetic profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a family history of lung cancer or those who have been identified as at high risk due to genetic factors.
Not a fit: Patients with lung cancer who do not have identifiable epigenetic changes or genetic mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate predictions of lung cancer risk and personalized treatment options for patients.
How similar studies have performed: Previous research has shown promising results in understanding the role of epigenetics in cancer, suggesting that this approach could yield valuable insights.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Lesch, Bluma J — Yale University
- Study coordinator: Lesch, Bluma J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.